#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Salvage Treatment and the Role of Transplantation in Lymphomas


Authors: D. Pohlreich;  B. Vacková;  R. Pytlík;  M. Trnková;  M. Trněný
Authors place of work: I. interní klinika –  klinika hematologie 1. LF UK a VFN v Praze
Published in the journal: Klin Onkol 2015; 28(Supplementum 3): 95-104
doi: https://doi.org/10.14735/amko20153S95

Summary

Despite achieving promising treatment results in patients with lymphoma, there is still a significant proportion of patients who relapse or have refractory disease. Salvage therapy followed by high dose treatment with autologous stem‑ cell transplantation is the standard of care in many of them. The role allogeneic stem‑ cell transplantation, especially after reduced intensity conditioning, is under extensive investigation. This review article presents current knowledge and recommendation in the salvage treatment of relapsed/ refractory lymphomas.

Key words:
refractory/ relapsed lymphoma –  Hodgkin’s lymphoma –  diffuse large B‑ cell lymphoma –  follicular lymphoma –  T-cell non-Hodgkin lymphoma –  autologous stem cell transplantation –  allogeneic hematopoietic stem cell transplantation

This work was supported by research projects NT12193-5/2011, NT11299-6/2010 and NT13072-4/2012.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
27. 9. 2015

Accepted:
29. 9. 2015


Zdroje

1. Kuruvil­la J. Standard therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2009; 497– 506. doi: 10.1182/ asheducation‑ 2009.1.497.

2. Schmitz N, Pfistner B, Sextro M et. al. Aggres­sive conventional chemotherapy compared with high‑dose chemotherapy with autologous haemopoietic stem‑ cel­l transplantation for relapsed chemosensitive Hodgkin‘s disease: a randomised trial. Lancet 2002; 359(9323): 2065– 2071.

3. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone‑ mar­row transplantation in relapsed and resistant Hodgkin‘s disease: results of a BNLI randomised trial. Lancet 1993; 341(8852): 1051– 1054.

4. Jost­ing A, Ruef­fer U, Franklin J et al. Prognostic factors and treatment outcome in primary progres­sive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000; 96(4): 1280– 1286.

5. Jost­ing A, Mul­ler H, Brochman­n P et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin‘s lymphoma. J Clin Oncol 2010; 28(34): 5074– 5080. doi: 10.1200/ JCO.2010.30.5771.

6. Kuruvil­la J, Keat­ing A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011; 117(16): 4208– 4217. doi: 10.1182/ blood‑ 2010‑ 09‑ 288373.

7. Jabbour E. Hos­ing C, Ayers G et al. Pretransplant positive positron emis­sion tomography/ gal­lium scans predict poor outcome in patients with recur­rent/ refractory Hodgkin lymphoma. Cancer 2007; 109(12): 2481– 2489.

8. Moskowitz AJ, Yahalom J, Kewalramani T et al. Pretransplantation functional imag­ing predicts outcome fol­low­ing autologous stem cel­l transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010; 116(23): 4934– 4947. doi: 10.1182/ blood‑ 2010‑ 05‑ 282756.

9. Reece DE, Barnett MJ, Con­nors JM et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide fol­lowed by autologous bone mar­row transplantation for relapsed Hodgkin‘s disease. J Clin Oncol 1991; 9(10): 1871– 1879.

10. Visani G, MalerbaL, Stefani PM et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cel­l transplantation is safe and ef­fective for resistant/ relapsed lymphoma patients. Blood 2001; 118(12): 3419– 3425. doi: 10.1182/ blood‑ 2011‑ 04‑ 351924.

11. Fung HC, Stif­f P, Schriber J et al. Tandem autologous stem cel­l transplantation for patients with primary refractory or poor risk recur­rent Hodgkin lymphoma. Biol Blood Mar­r Transplant 2007: 13(5): 594– 600.

12. Morschhauser F, Brice P, Fermé C et al. Risk‑adapted salvage treatment with single or tandem autologous stem‑ cel­l transplantation for first relapse/ refractory Hodgkin‘s lymphoma: results of the prospective multicenter H96 trial by the GELA/ SFGM study group. J Clin Oncol 2008; 26(36): 5980– 5897. doi: 10.1200/ JCO.2007.15.5887.

13. Devil­lier R, Coso D, Castagna L et al. Positron emis­sion tomography response at the time of autologous stem cel­l transplantation predicts outcome of patients with relapsed and/ or refractory Hodgkin‘s lymphoma respond­ing to prior salvage therapy. Haematologica 2012; 97(7): 1073– 1079. doi: 10.3324/ haematol.2011.056051.

14. Pohlreich D, Vackova B, Trnkova M et al. Fifty percent cure rate in poor risk relapsed/ refractory Hodgkin lymphoma after tandem autologous stem cel­l transplantation. EBMT 2014: abstr. 2381.

15. Gajewski JL, Phil­lips GL, Sobocinski KA et al. Bone mar­row transplants from HLA‑identical siblings in advanced Hodgkin‘s disease. J Clin Oncol 1996: 14(2): 572– 578.

16. Milpied N, Field­ing AK, Pearce RM et al. Al­logeneic bone mar­row transplant is not better than autologous transplant for patients with relapsed Hodgkin‘s disease. European Group for Blood and Bone Mar­row Transplantation. J Clin Oncol 1996: 14(4): 1291– 1296.

17. Sureda A, Robinson S, Canals C et al. Reduced‑ intensity condition­ing compared with conventional al­logeneic stem‑ cel­l transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lamphoma Work­ing Party of the European Group for Blood and Mar­row Transplantation. J Clin Oncol 2008: 26(3): 455– 462.

18. Robinson SP, Sureda A, Canals C et al. Reduced intensity al­logeneic stem cel­l transplantation for hodgkin’s lymphoma: Identification of prognostic factors predict­ing outcome. Haematol 2009; 94(2): 230– 238. doi: 10.3324/ haematol.13441.

19. Bur­roughs LM, O’Don­nel PV, Sandmaier BM et al. Comparison of outcomes of HLA‑matched related, unrelated, or HLA‑haploidentical related hematopoietic cel­l transplantation fol­low­ing nonmyeloablative condition­ing for relapsed or refractory Hodgkin lymphoma. Biol Blood Mar­row Transplantation 2008; 14(11): 1279– 1287. doi: 10.1016/ j.bbmt.2008.08.014.

20. Peggs KS, Kasvani I, Edwards N et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T‑ cel­l‑ depleted al­logeneic transplantation for Hodgkin’s lymfoma. J Clin Oncol 2011: 29(8): 971– 978. doi: 10.1200/ JCO.2010.32.1711.

21. Coif­fier B, Lepage E, Briere J et al. CHOP like chemotherapy plus rituximabcompared with CHOP alone inelderly patients with dif­fuse large‑ B‑ cel­l lymphoma. N Engl J Med 2002; 346(4): 235– 242.

22. Pfreundschuh M, Trümper L, Ostergorg A et al. CHOP‑like chemotherapy plus rituximab versus CHOP‑like chemotherapy alone inyoung patients with good‑ prognosis dif­fuse large‑ B‑ cel­l lymphoma: a randomized control­led trial by the MabThera International Trial Group. Lancet Oncol 2006; 7(5): 379– 391.

23. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone mar­row transplantation as compared with salvage chemotherapy in relapses of chemotherapy‑ sensitive non‑Hodkin’s lymphoma. N Eng J Med 1995; 333(23): 1540– 1545.

24. Thieblemont C, Briere J, Mounier N et al. The germinal center/ activated B‑ cel­l subclas­sification has a prognostic impact for response to salvage therapy in relapsed/ refractory dif­fuse large B‑ cel­l lymphoma: a bio­‑ CORAL study. J Clin Oncol 2011; 29(31): 4079– 4087. doi: 10.1200/ JCO.2011.35.4423.

25. Gis­selbrecht C, Glas­s B, Mounier N et al. Salvage regiments with autologous transplantation for relapsed large B‑ cel­l lymphomain the rituximab era. J Clin Oncol 2010; 28(27): 4184– 4190. doi: 10.1200/ JCO.2010.28.1618.

26. Crump M, Kuruvil­la J, Couban S et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem‑ cel­l transplantation for relapsed and refractory aggres­sive lymphomas: NCIC‑ CTG LY.12. J Clin Oncol 2014: 32(31): 3490– 3496. doi: 10.1200/ JCO.2013.53.9593.

27. Martín A, Conde E, Arnan M et al. R‑ ESHAP as salvage therapy for patients with relapsed or refractory dif­fuse large B‑ cel­l lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/ TAMO study. Haematologica 2008; 93(12): 1829– 1836. doi: 10.3324/ haematol.13440.

28. Kewalramani T, Zelenetz AD, Nimer SD et al. Rituximab and ICE as second‑line therapy before autologous stem cel­l transplantation for relapsed or primary refractory dif­fuse large B‑ cel­l lymphoma. An­n Hematol 2007; 86: 107– 115.

29. Vel­lenga E, van Putten WT, van’t Veer MB et al. Rituximab improves the treatment results of DHAP‑ VIM‑ DHAP and ASCTin relapsed/ progres­sive agres­sive CD 20+ NHL: a prospective randomised HOVON trial. Blood 2008; 111(2): 537– 543.

30. Van Kampen RJ, Canals C, Schouten HC et al. Al­logeneic stem‑ cel­l transplantation as salvage therapy for patients with dif­fuse large B‑ cel­l lymphoma Relaps­ing after an autologous stem‑ cel­l transplantation: an analysis of the Euuropean Group for Blood and Mar­row Transplantation registry. J Clin Oncol 2011; 29(10): 1342– 1348. doi: 10.1200/ JCO.2010.30.2596.

31. Freytes CO, Zhang MJ, Car­reras J et al. Outcome of lower‑ intensity al­logeneic transplantation in non‑Hodgkin lymphoma after autologous transplantation failure. Biol Blood Mar­row Transplant 2012; 18(8): 1255– 1264. doi: 10.1016/ j.bbmt.2011.12.581.

32. Sureda A, Bader P, Cesaro S et al. Indications for al­lo‑  and auto‑ SCT for haematological diseases, solid tumours and im­mune disorders: cur­rent practice in Europe, 2015. Bone Mar­r Transpl 2015: 50(8): 1037– 1056. doi: 10.1038/ bmt.2015.6.

33. Al Khabori, de Almeida JR, Guyatt GH et al. Autologous stem cel­l transplantation in fol­licular lymphoma: A systematic review and meta‑analysis. J Natl Cancer Inst 2012; 104(1): 18– 28. doi: 10.1093/ jnci/ djr450.

34. Schouten HC, Qian W, Kvaloy S et al. High‑dose therapy improves progres­sion‑free survival and survival in relapsed fol­licular non‑Hodgkin‘s lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21(21): 3918– 3927.

35. Sebban C, Brice P, Delarue R et al. Impact of rituximab and/ or high‑dose therapy with autotransplant at time of relapse in patients with fol­licular lymphoma: a GELA study. J Clin Oncol 2008; 26(21): 3614– 3620. doi: 10.1200/ JCO.2007.15.5358.

36. Kornacker M, Stum­m J, Pott C et al. Characteristics of relapse after autologous stem‑ cel­l transplantation for fol­licular lymphoma: a long‑term fol­low‑up. An­n Oncol 2009; 20(4): 722– 728. doi: 10.1093/ an­nonc/ mdn691.

37. Pettengel­l R, Schmitz N, Gis­selbrecht C et al. Rituximab purg­ing and/ or maintenance in patients undergo­ing autologous transplantation for relapsed fol­licular lymphoma: a prospective randomized trial from the lymphoma work­ing party of the European group for blood and mar­row transplantation. J Clin Oncol 2013; 31(13): 1624– 1630. doi: 10.1200/ JCO.2012.47.1862.

38. Vose J, Armitage J, Weisenburger D et al. International peripheral T‑ cel­l and natural kil­ler/ T‑ cel­l lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26(25): 4124– 4130. doi: 10.1200/ JCO.2008.16.4558.

39. Schmitz N, Trümper L, Ziepert M et al. Treatment and prognosis of mature T‑ cel­l and NK‑ cel­l lymphoma: an analysis of patients with T‑ cel­l lymphoma treated in studies of the German High‑Grade Non‑ Hodgkin Lymphoma Study Group. Blood 2010; 116(18): 3418– 3425. doi: 10.1182/ blood‑ 2010‑ 02‑ 270785.

40. Janikova A, Bortlicek Z, et al. CHOEP versus CHOP gives better results in first‑line therapy of t‑ cel­l lymphoma. A retrospective analysis from czech lymphoma study group (CLSG) database. Hematological Oncology 2015; 33 (Suppl 1): abstr. 99.

41. Cor­radini P, Tarel­la C, Zal­lio F et al. Long‑term fol­low‑up of patients with peripheral T‑ cel­l lymphomas treated up‑ front with high dose chemotherapy fol­lowed by autologous stem cel­l transplantaion. Leukemia 2006; 20(9): 1533– 1538.

42. Rodrigues J, Conde E, Gutiér­rez A et al. Frontline autologous stem cel­l transplantation in high‑risk peripheral T‑ cel­l lymphoma: a prospective study from The Gel‑ Tamo Study Group. Eur J Haematol 2007; 79(1): 32– 38.

43. Reimer P, Rüdiger T, Geis­singer E et al. Autologous stem cel­l transplantation as first‑line therapy in peripheral T‑ cel­l lymphomas: results of a prospective multicenter study. J Clin Oncol 2009; 27(1): 106– 113. doi: 10.1200/ JCO.2008.17.4870.

44. d‘Amore F, Relander T, Lauritzsen GF et al. Up‑ front autologous stem‑ cel­l transplantation in peripheral T‑ cel­l lymphoma: NLG‑ T‑ 01. J Clin Oncol 2012; 30(25): 3093– 3099. doi: 10.1200/ JCO.2011.40.2719.

45. Rodrigues J, Cabal­lero MD, Gutiér­rez A et al. High‑dose chemotherapy and autologous stem cel­l transplantation in peripheral T‑ cel­l lymphoma: the GEL‑ TAMO experience. An­n Oncol 2003; 14(12): 1768– 1775.

46. Rodrigues J, Conde E, Gutiér­rez A et al. The adujusted International Prognostic Index and beta‑2– microglobulin predict the outcome after autologous stem cel­l transplantation in relapsing/ refraktory peripheral T‑ cel­l lymphoma. Haematologica 2007; 92(8): 1067– 1074.

47. Chen A, McMil­lan A, Negrin RS et al. Long‑term results af autologous hematopoietic cel­l transplantation for peripheral T‑ cel­l lymphoma: the Stanford experience. Biol Blood Mar­row Transplant 2008; 14(7): 741– 747. doi: 10.1016/ j.bbmt.2008.04.004.

48. Kyriakou C, Canals C, Goldstone A et al. High‑dose therapy and autologous stem‑ cel­l transplantation in angioimunoblaststic lymphoma: complete remis­sion at transplantation is the major determinant of outcome –  Lymphoma Work­ing Party of the European Group for Blood and Mar­row Transplantation. J Clin Oncol 2008; 26(2): 218– 224. doi: 10.1200/ JCO.2007.12.6219.

49. Dodero A, Spina F, Narni F et al. Al­logeneic transplantation fol­low­ing a reduced intensity condition­ing regimen in relapsed/ refractory peripheral T‑ cel­l lymphomas: long term remis­sions and response to donor lymphocyte infusions support the role of a graft versus lymphoma ef­fect. Leukemia 2012; 26(3): 520– 526. doi: 10.1038/ leu.2011.240.

50. Valkova V, Benesova K, Vitek A et al. The results of al­logeneic transplants in patients with malignant lymphoma‑ a retrospective analysis of data from the Czech National Registry. Neoplasma 2009; 56(1): 76– 83.

51. Cor­radini P, Vitolo U, Rambaldi A et al. Intensified chemo‑ im­munotherapy with or without stem cel­l transplantation in newly dia­gnosed patients with peripheral T‑ cel­l lymphoma. Leukemia 2014; 28(9): 1885– 1891. doi: 10.1038/ leu.2014.79.

52. Schmitz N, Nickelsen M, Altman­n B et al. Al­logeneic or autologous transplantation as first‑line therapy for younger patients with peripheral T‑ cel­l lymphoma: results of the interim analysis of the AATT trial. J Clin Oncol ASCO Meet­ing Abstracts 2015; 33 (15 Suppl): 8507.

Štítky
Paediatric clinical oncology Surgery Clinical oncology

Článok vyšiel v časopise

Clinical Oncology

Číslo Supplementum 3

2015 Číslo Supplementum 3
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#